TY - JOUR
T1 - Variability in Plus Disease Diagnosis using Single and Serial Images
AU - Imaging and Informatics in Retinopathy of Prematurity (i-ROP) Research Consortium
AU - Cole, Emily D.
AU - Park, Shin Hae
AU - Kim, Sang Jin
AU - Kang, Kai B.
AU - Valikodath, Nita G.
AU - Al-Khaled, Tala
AU - Patel, Samir N.
AU - Jonas, Karyn E.
AU - Ostmo, Susan
AU - Coyner, Aaron
AU - Berrocal, Audina
AU - Drenser, Kimberly A.
AU - Nagiel, Aaron
AU - Horowitz, Jason D.
AU - Lee, Thomas C.
AU - Kalpathy-Cramer, Jayashree
AU - Chiang, Michael
AU - Campbell, J. Peter
AU - Chan, R. V.Paul
AU - Sonmez, Kemal
AU - Chan, RV Paul
AU - Jonas, Karyn
AU - Horowitz, Jason
AU - Coki, Osode
AU - Eccles, Cheryl Ann
AU - Sarna, Leora
AU - Orlin, Anton
AU - Negron, Catherin
AU - Denser, Kimberly
AU - Cumming, Kristi
AU - Osentoski, Tammy
AU - Check, Tammy
AU - Zajechowski, Mary
AU - Lee, Thomas
AU - Kruger, Evan
AU - McGovern, Kathryn
AU - Simmons, Charles
AU - Murthy, Raghu
AU - Galvis, Sharon
AU - Rotter, Jerome
AU - Chen, Ida
AU - Li, Xiaohui
AU - Taylor, Kent
AU - Roll, Kaye
AU - Erdogmus, Deniz
AU - Ioannidis, Stratis
AU - Martinez-Castellanos, Maria Ana
AU - Salinas-Longoria, Samantha
AU - Romero, Rafael
AU - Arriola, Andrea
N1 - Funding Information:
M.F.C.: Support – National Institutes of Health; Grants – National Institutes of Health, National Science Foundation, Genentech; Consulting fees – Novartis; Equity owner – Inteleretina LLC
Funding Information:
Supported by grants R01EY19474, K12EY027720, P30 EY001792, and P30EY10572 from the National Institutes of Health (Bethesda, Maryland), grants SCH-1622679, SCH-1622542, and SCH-1622536 from the National Science Foundation (Arlington, Virginia), unrestricted departmental funding, and a Career Development Award (J.P.C.) from Research to Prevent Blindness (New York, New York). J.K.-C.: Support – National Institutes of Health; Grants – Genentech; Royalties – Boston AI. M.F.C.: Support – National Institutes of Health; Grants – National Institutes of Health, National Science Foundation, Genentech; Consulting fees – Novartis; Equity owner – Inteleretina LLC J.P.C.: Grants – National Institutes of Health, Research to Prevent Blindness; Consulting fees – Boston AI; Co-founder – Siloam Vision; Equity owner – Siloam Vision; Support – Genentech. R.V.P.C.: Grants – National Institutes of Health, Research to Prevent Blindness; Leadership role – Vit Buckle Society, Helen Keller International, Prevent Blindness America; Equity owner – Siloam Vision; Scientific Advisory Board – NeoLight LLC; Consulting fees – Alcon; Co-founder – Siloam Vision; Support – Genentech. Obtained funding: Chan, Campbell, Chiang
Publisher Copyright:
© 2022
PY - 2022/12
Y1 - 2022/12
N2 - Purpose: To assess changes in retinopathy of prematurity (ROP) diagnosis in single and serial retinal images. Design: Cohort study. Participants: Cases of ROP recruited from the Imaging and Informatics in Retinopathy of Prematurity (i-ROP) consortium evaluated by 7 graders. Methods: Seven ophthalmologists reviewed both single and 3 consecutive serial retinal images from 15 cases with ROP, and severity was assigned as plus, preplus, or none. Imaging data were acquired during routine ROP screening from 2011 to 2015, and a reference standard diagnosis was established for each image. A secondary analysis was performed using the i-ROP deep learning system to assign a vascular severity score (VSS) to each image, ranging from 1 to 9, with 9 being the most severe disease. This score has been previously demonstrated to correlate with the International Classification of ROP. Mean plus disease severity was calculated by averaging 14 labels per image in serial and single images to decrease noise. Main Outcome Measures: Grading severity of ROP as defined by plus, preplus, or no ROP. Results: Assessment of serial retinal images changed the grading severity for > 50% of the graders, although there was wide variability. Cohen's kappa ranged from 0.29 to 1.0, which showed a wide range of agreement from slight to perfect by each grader. Changes in the grading of serial retinal images were noted more commonly in cases of preplus disease. The mean severity in cases with a diagnosis of plus disease and no disease did not change between single and serial images. The ROP VSS demonstrated good correlation with the range of expert classifications of plus disease and overall agreement with the mode class (P = 0.001). The VSS correlated with mean plus disease severity by expert diagnosis (correlation coefficient, 0.89). The more aggressive graders tended to be influenced by serial images to increase the severity of their grading. The VSS also demonstrated agreement with disease progression across serial images, which progressed to preplus and plus disease. Conclusions: Clinicians demonstrated variability in ROP diagnosis when presented with both single and serial images. The use of deep learning as a quantitative assessment of plus disease has the potential to standardize ROP diagnosis and treatment.
AB - Purpose: To assess changes in retinopathy of prematurity (ROP) diagnosis in single and serial retinal images. Design: Cohort study. Participants: Cases of ROP recruited from the Imaging and Informatics in Retinopathy of Prematurity (i-ROP) consortium evaluated by 7 graders. Methods: Seven ophthalmologists reviewed both single and 3 consecutive serial retinal images from 15 cases with ROP, and severity was assigned as plus, preplus, or none. Imaging data were acquired during routine ROP screening from 2011 to 2015, and a reference standard diagnosis was established for each image. A secondary analysis was performed using the i-ROP deep learning system to assign a vascular severity score (VSS) to each image, ranging from 1 to 9, with 9 being the most severe disease. This score has been previously demonstrated to correlate with the International Classification of ROP. Mean plus disease severity was calculated by averaging 14 labels per image in serial and single images to decrease noise. Main Outcome Measures: Grading severity of ROP as defined by plus, preplus, or no ROP. Results: Assessment of serial retinal images changed the grading severity for > 50% of the graders, although there was wide variability. Cohen's kappa ranged from 0.29 to 1.0, which showed a wide range of agreement from slight to perfect by each grader. Changes in the grading of serial retinal images were noted more commonly in cases of preplus disease. The mean severity in cases with a diagnosis of plus disease and no disease did not change between single and serial images. The ROP VSS demonstrated good correlation with the range of expert classifications of plus disease and overall agreement with the mode class (P = 0.001). The VSS correlated with mean plus disease severity by expert diagnosis (correlation coefficient, 0.89). The more aggressive graders tended to be influenced by serial images to increase the severity of their grading. The VSS also demonstrated agreement with disease progression across serial images, which progressed to preplus and plus disease. Conclusions: Clinicians demonstrated variability in ROP diagnosis when presented with both single and serial images. The use of deep learning as a quantitative assessment of plus disease has the potential to standardize ROP diagnosis and treatment.
KW - Retinopathy of prematurity
KW - ROP imaging
KW - ROP progression
KW - ROP screening
KW - telemedicine
UR - http://www.scopus.com/inward/record.url?scp=85139684460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139684460&partnerID=8YFLogxK
U2 - 10.1016/j.oret.2022.05.024
DO - 10.1016/j.oret.2022.05.024
M3 - Article
C2 - 35659941
AN - SCOPUS:85139684460
SN - 2468-7219
VL - 6
SP - 1122
EP - 1129
JO - Ophthalmology Retina
JF - Ophthalmology Retina
IS - 12
ER -